Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-SSO110 in ES-SCLC and MCC
NCT06939036Phase 2Terminated
- Sponsor
- Ariceum Therapeutics
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of 225Ac-SSO110 in small cell lung cancer (SCLC) and Merkel cell carcinoma (MCC), sponsored by Ariceum Therapeutics. Primary endpoints: Safety, tolerability, and Recommended Phase 2 Dose (RP2D) of 225Ac-SSO110 in combination with SoC at 42 days, Preliminary anti-tumor activity of 225Ac-SSO110 in combination with SoC at RP2D at 42 days and 1 more. Started Jul 2025; status: terminated.
02
Drugs
225Ac-SSO110
03
Conditions
small cell lung cancer (SCLC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT06939036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939036.